Recent genomic analyses have classified invasive breast cancers into several subtypes that can be approximated using surrogate immunohistochemical (IHC) markers in clinical practice: luminal A‐like, luminal B‐like, HER2‐positive, and triple negative (TN) 6. This evidence concerns the gene ERBB2 and breast cancer.